11th Global Drug Delivery & Formulation (DDF) Summit

11th Global Drug Delivery & Formulation (DDF) Summit is organized by Mark Allen Group (MAG). The session is held from Mar 09 - 11, 2020 at Maritim proArte Hotel Berlin, Berlin, Germany. 

Who attends the DDF Summit

The targeted audience for the session includes,

By Job type,

• R&D 
• Analytical Development 
• Pharmaceutical Development 
• Formulation
• Development 
• Technical Development 
• Device Development 
• Process Development 
• Drug Development 
• CMC 
• Human Factors 
• Innovation 
• Business Development

By company type:
• Pharmaceuticals Delivery /
• Formulation Services
• Universities

Description:
The perfect mix: The DDF Summit will unite together the driving formulation progress and drug delivery scientists of both industry and academia to yield and discuss their current work
Quality content: The program is carried with thoughtfully chosen talks on topics such as the diverse challenges faced 

Invaluable networking: The DDF community is open, friendly and portrays an amazingly valuable network of scientists working at the forefront of their field. There is plenty of networking time in order to help you make strengthened connections.

Tailor your experience: Four parallel streams in the session will render an opportunity to personalize the data and dive deep into the topics relevant to your challenges. Choose from Small Molecules, Biologics, Technology & Innovation or Device Development.

The right size: The 2020  DDF Summit is limited to just 500 people to sustain the quality of the networking and comfort for participants. This means that there will only be 250 delegate tickets available. So, don’t waste time in getting yours.

Key themes for 2020 include:
• New modalities research opportunities and challenges
• Personalized therapies, mRNA, Cell and gene therapies
• Analytical techniques for biotherapeutics
• 3D printing, flexible manufacturing techniques, continuous manufacturing
• Multivariate analysis techniques, production process optimization, digitalization of
• pharmaceutical development
• mAb and bispecific formulation development
• Oral delivery of biologics and other routes
• Device development, microneedles, connected devices
• Integrating human factors into device development, behavioral design

Additional details will be posted as soon as information is available.